Home / Expertise / Life Sciences & Healthcare
Lab

Life Sciences & Healthcare

United Kingdom

Discovery, innovation, market awareness and understanding are key to those life sciences and healthcare entities providing services and finance towards, and developing therapies and services for, the improvement of patient outcomes.

Due to the highly regulated nature of the industry, as an operator, investor, adviser, developer or licensee, you will be dealing with complex legal and regulatory requirements to launch, maintain and deliver your products and services to the market.

Our Life Sciences team is immersed in the sector and we appreciate our clients' technology; we are not just lawyers, we are immunologists, geneticists, chemists and engineers. With this background we are ideally placed to really understand your business, how it is changing and what you want from a trusted advisor. Highly relevant to this sector is our fully integrated European patent attorney practice. Spanning multiple disciplines, both legal and scientific, our lawyers and patent attorneys operate as one team with a common outlook and objective for our clients - providing pragmatic, innovative and effective advice, efficiently.

Our Healthcare team is truly immersed in the sector with over 25 years of advising and shaping the sector through in depth experience, knowledge and sector associations and collaborations. We have significant experience of working within the public and private sectors, giving us a complete perspective of the issues you face, allowing us to offer you commercial and well rounded advice.

With active memberships in major industry bodies such as the ABPI, ABHI, BIVDA, EUCOMED / MedTech Europe, Healthcare UK and the BPF, we help shape the legal and compliance frameworks impacting the life sciences and healthcare sectors.

As well as clients' significant, complex and strategic transactional, financing and structuring matters, we regularly advise on day-to-day business operations, covering areas such as public procurement, tax, competition, IP protection, exploitation and enforcement, product liability, supply chain, outsourcing and other commercial agreements and employment and pensions matters, as well as regulatory, disputes, risk and compliance advice. Truly a full service.

Read more Read less

"A one-stop-shop for us: its remarkable and successful mix of talent makes it stand out from the rest, and makes our lives much easier."

Chambers UK, 2015

Choose area

    Biotech

    Recent years have seen an increase in the numbers of biotech IPOs and more investment in the sector, however it can still be challenging accessing the finance necessary to fund R&D and to bring products to the market. As part of the biotech industry you will expect your lawyers to assist you in tackling these difficult financing and market challenges. Our team of sector specialists, including lawyers with technical backgrounds, understands the commercial drivers in this industry and can advise you on the full spectrum of legal matters.

    Read more

    Devices & Diagnostics

    In an increasingly competitive healthcare market, medical device and diagnostics companies need to ensure return on investment when developing innovative and reliable medical technologies and services. Devices and diagnostics are subject to complex regulatory and compliance frameworks and are often subject to competitive tendering so you will need lawyers who can reliably advise on pragmatic, compliant solutions.

    Read more

    eHealth

    With technology and digital innovation at the forefront of many advancements in the lifesciences industry and in healthcare delivery, organisations look  to consistently push boundaries to bring products and services to both the consumer and professional market. However, the regulation of ehealth solutions, devices and services is often outpaced by the novelty and innovation in the solutions themselves and at CMS, we understand the challenges this presents.

    Read more

    Healthcare

    The healthcare sector in the UK and internationally continues to experience dynamic change underpinned by significant legal reforms. As an operator, investor, funder, developer or landlord in this sector, you are facing a highly regulated environment as well as significant public scrutiny.

    With increasing potential for the independent provision of health and social care along with an ageing population and technological advances, but with tightening public budgets, operating within the health and social care sectors presents both challenges and opportunities.
     

    Read more

    Pharmaceuticals

    With ever increasing costs of gaining marketing authorisations for new drugs, fewer opportunities for blockbuster products and ongoing pressure on pricing, operating successfully in the pharmaceutical sector can be challenging. Our sector-focused team, many of whom have technical backgrounds, are able to help clients overcome these challenges and maximise the commercial opportunities.

    Read more
    equIP Life Sci­ences: from lab bench to busi­ness
    High­lights of our ex­per­i­ence in Life Sci­ences & Health­care...
    Law-Now: Lifes­ci­ences
    Vis­it Law-Now for leg­al know-how and com­ment­ary

    Feed

    Show only
    13 Jan 20
    High­lights of our ex­per­i­ence in Health­care
    31 Mar 20
    Coronavir­us Act 2020
    The Coronavir­us Bill has re­ceived Roy­al As­sent in near re­cord time for such a wide ran­ging piece of le­gis­la­tion.  The Act gives ef­fect to the gov­ern­ment’s ac­tion plan for re­spond­ing to the COV­ID-19...
    November 2019
    equIP Life Sci­ences: from lab bench to busi­ness
    Sup­port­ing the growth of com­pan­ies across bi­otech,...
    27 Mar 20
    Man­aging clin­ic­al tri­als un­der COV­ID-19: New EU guid­ance is­sued for...
    The COV­ID-19 pan­dem­ic has had a dra­mat­ic im­pact on European health sys­tems, whose pri­or­ity first and fore­most is the treat­ment of pa­tients suf­fer­ing from this dis­ease both in the in-pa­tient and out-pa­tient...
    30 October 2019
    CMS ad­vises Ad­vent In­ter­na­tion­al and Zentiva on ac­quis­i­tion...
    26 Mar 20
    Buy­ing in a crisis – UK and Scot­tish Gov­ern­ments cla­ri­fy how the pub­lic...
    Cor­rect as of 5pm on 26/03/2020. This art­icle is be­ing main­tained. Use­ful cla­ri­fic­a­tion on the ap­plic­a­tion of the pro­cure­ment rules to the cur­rent COV­ID-19 crisis has now been pub­lished by the UK and...
    1 October 2019
    Health­care M&A
    Get­ting the Deal Through
    26 Mar 20
    European Com­mis­sion pro­poses delay­ing the May 2020 ap­plic­a­tion of...
    The European Com­mis­sion has con­firmed it is work­ing on a pro­pos­al to delay for one year the date of ap­plic­a­tion of the new EU Med­ic­al Devices Reg­u­la­tion 2017/745/EU (the “MDR”) in light of the Cov­id-19...
    29 August 2019
    UK Can­nabis In­dustry
    24 Mar 20
    Cov­id-19: Help for busi­nesses
    The Gov­ern­ment has im­ple­men­ted cer­tain meas­ures to ease the li­quid­ity pres­sures stem­ming from the Cov­id-19 out­break. These meas­ures, in­clud­ing the new pro­grammes for debt and wage sup­port, are amongst...
    August 2019
    Health in­fra­struc­ture mov­ing for­ward
    19 Mar 20
    COV­ID-19: pro-act­ive tax man­age­ment guid­ance
    The Chan­cel­lor an­nounced a raft of COV­ID-19 sup­port meas­ures and tax as­sist­ance in the Budget on 11 March and fur­ther meas­ures on 17 March in re­sponse to the nov­el COV­ID-19. CMS has pro­duced the table...